Apathy in Parkinson's disease

Psychiatry of Parkinson's Disease

Volumn 27, Issue , 2012, Pages 27-40

  Leroi, Iracema ^a,b   David, Renaud ^c,d   Robert, Philippe H ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LANCASHIRE CARE NHS FOUNDATION TRUST   (United Kingdom)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84898778686     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000331524     Document Type: Chapter

References (78)

1. Pluck GC, Brown RG: Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73:636-643.
2. Dujardin K, Sockeel P, Devos D, et al: Characteristics of apathy in Parkinson's disease. Mov Dis 2007;22: 778-784.
3. Aalten P, Verhey F, Boziki M, et al: Neuropsychiatric syndromes in dementia: results from the European Alzheimer disease consortium. Dement Geriatr Cogn Disord 2007;24:457-463.
4. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E: Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999;14:866-874.
5. Van Reekum R, Stuss DT, Ostrander R: Apathy: why care? J Neuropsychiatry Clin Neurosci 2005;17:7-19.
6. Srikanth S, Nagaraja AV, Ratnavalli E: Neuropsychiatric symptoms in dementia-frequency, relationship to dementia severity and comparison in Alzheimer's disease, vascular dementia and frontotemporal dementia. J Neurol Sci 2005;236:43-48.
7. Mulin E, Leone E, Dujardin K, Delliaux, et al: Diagnostic criteria for apathy in clinical practice. Int J Geriatr Psychiatry 2011;26:158-165.
8. Starkstein SE, Petracca G, Chemerinski E, Kremer J: Syndromic validity of apathy in Alzheimer's disease. Am J Psychiatry 2001;158:872-877.
9. Levy R, Dubois B: Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 2006;16:916-928.
10. Robert PH, Clairet S, Benoit M, Koutaich J, Bertogliati C, Tible O, et al: The Apathy Inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry 2002;17:1099-1105.
11. Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy Evaluation Scale. Psych Res 1991;38:143-162.
12. Starkstein SE, Jorge R, Mizrahi R, Robinson RG: A prospective longitudinal study of apathy in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006;77:8-11.
13. Robert P, Robert P, Onyike CU, Leentjens AFG, Dujardin K, Aalten P, et al: Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry 2009;24: 98-104.
14. Verhey F, Aalten P De Vugt ME: Incidence, prevalence and persistence of behavioural disorders in dementia. Int Psychogeriatr 2003;15(suppl) S034-S002.
15. Drijgers RL, Dujardin K, Reijnders JSAM, et al: Validation of diagnostic criteria for apathy in Parkinson's disease. Parkinsonism Relat Disord 2010;16:656-660.
16. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
17. Sockeel P, Dujardin K, Devos D, Denève C, Destée A, Defebvre L: The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Pakinson's disease. J Neurol Neurosurg Psychiatry 2006;77:579-584.
18. Gallagher DA, Lees AJ, Schrag A: Letter to the Editor: Unified Parkinson's Disease Rating Scale (UPDRS) part I as a screening and diagnostic instrument for apathy in patients with Parkinson's disease. Parkinsonism Rel Dis 2008;14:586-587.
19. Fahn S, Elton RL, UPDRS Development Committee: Unified Parkinson's Disease Rating Scale; in Fahn S, Marsden CD, Calne DB, Goldstein M (eds): Recent Developments in Parkinson's Disease. Florham Park, Macmillan, 1987, pp 153-163.
20. Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, et al: Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2008;23:2004-2014.
21. Starkstein SE, Mayberg HS, Preziosi TJ, et al: Reliability, validity and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992;4:134-139.
22. Clarke DE, Ko JY, Kuhl EA, van Reekum R, Salvador R, Marin RS: Are the available apathy measures reliable and valid? A review of the psychometric evidence. J Psychosom Res 2011;70:73-97.
23. Singer E: Social costs of Parkinson's disease. J Chronic Dis 1973;26:243-254.
24. Czernecki V, Schüpbach M, Yaici S, Lévy R, Bardinet E, Yelnik J, Dubois B, Agid Y: Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008;23: 964-969.
25. Tekin S, Cummings JL: Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res 2002;53:67-654.
26. Devinsky O, Morrell MJ, Vogt BA: Contributions of anterior cingulate cortex to behaviour. Brain 1995; 118:279-306.
27. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy RL, Dubois B: Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 2002;40:2257-2267.
28. David R, Koulibaly M, Benoit M, et al: Striatal dopamine transporter levels correlate with apathy in neurodegenerative disease. A SPECT study with partial volume effect correction. Clin Neurol Neurosurg 2008;110:19-24.
29. Leentjens AFG, Scholtissen B, Vreeling FW, Verhey FRJ: The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neuropsychopharmacology 2006;31:1009-1015.
30. Hoehn-Saric R, Lipsey JR, McLeod DR: Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol 1990;10:343-345.
31. Wongpakaran N, van Reekum R, Wongpakaran T, Clarke D: Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study. Ann Gen Psychiatry 2007;6:7.
32. Cummings JL: Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003;11:131-145.
33. Landes AM, Sperry SD, Strauss ME, Geldmacher DS: Apathy in Alzheimer's disease. J Am Geriatr Soc 2001;49:1700-1707.
34. Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, Paulsen JS, Litvan I: Apathy is not depression. J Neuropsych Clin Neurosci 1998; 10:314-319.
35. Mayeux R, Stern Y, Sano M, Cote L, Williams JB: Clinical and biochemical correlates of bradyphrenia in Parkinson's disease. Neurol 1987;37:1130-1134.
36. Marin RS, Firinciogullari S, Biedrzycki RC: The sources of convergence between measures of apathy and depression. J Affect Disord 1993;29:117-124.
37. Starkstein SE, Ingram L, Garau ML, Misrahi R: On the overlap between apathy and depression in dementia. J Neurol Neurosurg Psychiatry 2005;76: 1070-1074.
38. Naville F: Études sur les complications et les séquelles mentales de l'encéphalite épidémique. La bradyphrénie. Encéphale 1922;17:369-375.
39. Duffy JD, Campbell JJ: The regional prefrontal syndromes: a theoretical and clinical overview. J Neuropsychiatry Clin Neurosci 1994;6:379-387.
40. Kuzis G, Sabe L, Tiberti C, Dorrego F, Starkstein SE: Neuropsychological correlates of apathy and depression in patients with dementia. Neurol 1999;52: 1403-1407.
41. Sperry SD, Strauss ME, Landes AM: Relation of apathy to depression, cognition, and daily function in dementia. J Int Neuropsychol Soc 2001;7:190.
42. Dujardin K, Sockeel P, Delliaux M, Destée A, Defebvre L: Apathy may herald cognitive decline and dementia in Parkinson's disease. Mov Disord 2009;24:2391-2397.
43. Robert PH, Berr C, Volteau M, et al: Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease: a one-year follow-up study. Clin Neurol Neurosurg 2006;108:733-736.
44. Mulin E, David R, Rivet A, Friedman L, et al: Apathy assessment using ambulatory actigraphy short-time recording in mild Alzheimer's disease. Int Psychogeriatr Assoc 2009;21:S116.
45. Benoit M, Andrieu S, Lechowski L, et al: Apathy and depression in Alzheimer's disease are associated with functional deficit and psychotropic prescription. Int J Geriatr Psychiatry 2008;23:409-414.
46. Leroi I, Ahearn DJ, Andrews M, McDonald K, Byrne EJ, Burns A: Disability and quality of life in Parkinson's disease is strongly associated with behavioural disorders in Parkinson's disease. Age Aging, Epub ahead of print.
47. Holroyd S, Currie LJ, Wooten GF: Depression is associated with impairment of ADL, not motor function in Parkinson disease. Neurology 2005;64:2134-2135.
48. Holthoff VA, Beuthien-Baumann B, Kalbe E, et al: Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression. Biol Psychiatry 2005;57:412-421.
49. Carter JH, Stewart BJ, Lyons KS, Archbold PG: Do motor and non motor symptoms in PD patients predict caregiver strain and depression? Move Disord 2008;23:1211-1216.
50. Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, et al: Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress J Neurol Neurosurg Psychiatry 2007;78:36-42.
51. Leroi I, Harbishettar V, Andrews M, McDonald K, Byrne EJ, Burns A: Carer burden in apathy and impulse control disorders in Parkinson's disease. Int J Geriatr Psychiatry, in press.
52. Tariot PN, Cummings JL, Katz IR, et al: A randomized, double-blind placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-1599.
53. Gauthier S, Feldman H, Hecker J, et al: Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002;14:389-404.
54. Seltzer B, Zolnouni P, Nunez M, et al: Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004;61:1852-1856.
55. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L: Randomized placebocontrolled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8.
56. Emre M, Aarsland D, Albanese A, Byrne J, et al: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518.
57. McKeith I, Del Ser T, Spano P, et al: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.
58. Cummings JL, Koumaras B, Chen M, Mirski D: Effects of rivastigmine treatment on the neuropsychiatric and behavioural disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005;3:137-148.
59. Hermann N, Rabheru K, Want J, Binder C: Galantamine treatment of problematic behaviour in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 2005;13:527-534.
60. Cummings JL, Schneider E, Tariot PN, Graham SM: Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurol 2006;67:57-63.
61. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, et al: Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8:613-618.
62. Leroi I, Overshott R, Byrne, EJ, Daniel E, Burns A: Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 2009;24:1217-1240.
63. Padala PR, Burke WJ, Bhatia SC: Modafinil therapy for apathy in an elderly patient. Ann Pharmacother 2007;41:346-349.
64. Corcoran C, Wong ML, O'Keane V: Bupropion in the management of apathy. J Psychopharmacol 2004;18:133-135.
65. Drayton SJ, Davies K, Steinberg M, Leroi I, et al: Amantadine for executive dysfunction syndrome in patients with dementia. Psychosomatics 2004;45: 205-209.
66. Van Reekum R, Bayley M, Garner S, et al: N of 1 study: Amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj 1995;9:49-53.
67. Leentjens A, Koester J, Fruh B, et al: The effect of pramipexole on mood and motivational symptoms in Parkinson disease: a meta-analysis of placebocontrolled studies. Clin Ther 2009;31:89-98.
68. Drapier D, Drapier S, Sauleau P, et al: Does subthalamic nucleus stimulation induce apathy in Parkinson's disease? J Neurol 2006;253:1083-1091.
69. Castelli L, Perozzo P, Zibetti M, et al: Chronic deep brain stimulation of the subathalamic nucleus for Parkinson's disease: effects on cognition, mood, anxiety and personality traits. Eur Neurol 2006;55: 136-144.
70. Castelli L, Lanotte M, Zibetti M, et al: Apathy and verbal fluency in STN-stimulated PD patients: an observational follow-up study. J Neurol 2007;254: 1238-1243.
71. de Medeiros K, Robert P, Gauthier S, Stella F, Politis A, et al: The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr 2010;6:984-994.
72. Ott BR, Noto RB, Fogel BS: Apathy and loss of insight in Alzheimer's disease: a SPECT imaging study. JNNP 1996;8:41-46.
73. Craig AH, Cummings JL, Fairbanks L, Itti L, et al: Cerebral blood flow correlates of apathy in Alzheimer disease. Arch Neurol 1996;53:1116-1120.
74. Benoit M, Dygai I, Migneco O, Robert PH, Bertogliati C, Darcourt J, et al: Behavioral and psychological symptoms in Alzheimer's disease. Relation between apathy and regional cerebral perfusion. Dement Geriatr Cogn Disord 1999;10:511-517.
75. Benoit M, Koulibaly PM, Migneco O, Darcourt J, Pringuey DJ, Robert PH: Brain perfusion in Alzheimer disease with and without apathy: a SPECT study with statistical parametric mapping analysis. Psychiatry Res 2002;114:103-111.
76. Benoit M, Clairet S, Koulibaly PM, Darcourt J, Robert PH: Brain perfusion correlates of the apathy inventory dimensions of Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:864-869.
77. Lanctot KL, Moosa S, Herrmann N, et al: A SPECT study of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;24:65-72.
78. Marshall GA, Monserratt L, Harwood D, et al: Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol 2007; 64:1015-1020.